

2019

## Development and preliminary results of an Electronic Medical Record (EMR)-integrated smartphone telemedicine program to deliver asthma care remotely

Jennifer R. Mammen  
*University of Rhode Island, jmammen@uri.edu*

James J. Java

Jill Halterman

Marc N. Berliant

Amber Crowley  
Follow this and additional works at: [https://digitalcommons.uri.edu/nursing\\_facpubs](https://digitalcommons.uri.edu/nursing_facpubs)

The University of Rhode Island Faculty have made this article openly available.  
Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

### Terms of Use

This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our [Terms of Use](#).

### Citation/Publisher Attribution

Mammen, J. R., Java, J. J., Halterman, J., Berliant, M. N., Crowley, A., Frey, S. M.,...Arcolego, K. (2019). Development and preliminary results of an Electronic Medical Record (EMR)-integrated smartphone telemedicine program to deliver asthma care remotely. *Journal of Telemedicine and Telecare*. <https://doi.org/10.1177/1357633X19870025>  
Available at: <https://doi.org/10.1177/1357633X19870025>

This Article is brought to you for free and open access by the College of Nursing at DigitalCommons@URI. It has been accepted for inclusion in College of Nursing Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact [digitalcommons@etal.uri.edu](mailto:digitalcommons@etal.uri.edu).

---

---

**Authors**

Jennifer R. Mammen, James J. Java, Jill Halterman, Marc N. Berliant, Amber Crowley, Sean M. Frey, Marina Reznik, Jonathan M. Feldman, Judith D. Schoonmaker, and Kimberly Arcoleo

**Development and preliminary results of an Electronic Medical Record (EMR)-integrated smartphone telemedicine program to deliver asthma care remotely**

**Authors**

Jennifer R. Mammen, PhD NP-C<sup>1,2</sup>, James J. Java, PhD<sup>3</sup>, Jill Halterman, MD MPH<sup>4</sup>, Marc N. Berliant, MD<sup>5</sup>, Amber Crowley, PharmD, MS-MTM, BCPS, BCACP,<sup>5</sup> Sean M. Frey, MD MPH<sup>4</sup>, Marina Reznik, MD<sup>6</sup>, Jonathan M. Feldman, PhD<sup>6,7</sup>, Judith D. Schoonmaker, MS<sup>2</sup>, Kimberly Arcoleo, PhD MPH<sup>8,9</sup>

**Affiliations**

1. University of Rhode Island, College of Nursing, Kingston, RI
2. University of Rochester School of Nursing, Rochester, NY
3. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY
4. University of Rochester School of Medicine, Department of Pediatrics, Rochester NY, 14642
5. University of Rochester School of Medicine, Department of Internal Medicine
6. Albert Einstein College of Medicine, Children's Hospital at Montefiore, Department of Pediatrics, Division of Academic General Pediatrics, Bronx, NY, 10467
7. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY 10461
8. The Center for Innovation in Pediatric Practice, Research Institute at Nationwide Children's Hospital, Columbus, OH
9. The Ohio State University College of Medicine, Department of Pediatrics, Columbus, OH

**Statistical Analysis**

Statistical analysis conducted by Dr. Jennifer R. Mammen, PhD, NP-C, University of Rhode Island College of Nursing, University of Rochester, Rochester, NY, and by Dr. James J. Java, PhD, Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY.

**Corresponding Author:** Jennifer Mammen

[jmammen@uri.edu](mailto:jmammen@uri.edu)

University of Rhode Island College of Nursing,  
350 Eddy Street, Providence RI

**Counts**

Title: 15

Number of references: 48

Number of tables: 5

Number of figures: 1 plus 1 Supplemental online material

Word count abstract: 249

Word count paper: 2999

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

### **Figure legends**

Figure 1. Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based assessments during telemedicine visits (left), including built-in patient educational modules from the Let's Talk About Asthma series for smartphone (right)

### **Online supplemental materials legend**

Figure E2. Sample progress note auto-generated by the TEAMS CDSS tool

### **List of abbreviations used in the manuscript:**

COPD – Chronic obstructive pulmonary disease

CDSS – Clinical decision support software

EMR – Electronic Medical Record

EPR3 – Expert Panel Report 3

FEV1 – Forced expiratory volume in 1 second

MID – Minimum important difference

PCP – Primary care provider

PEF – Peak expiratory flow

PFM – Peak flow meter

TEAMS – Technology Enabled Asthma Management System

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

### Abstract

**Background:** Technology-based interventions that can function within real-world practice and improve outcomes *without* increasing provider burden are needed, yet few successfully cross the research-to-practice divide. This paper describes the process of developing a clinically-integrated smartphone-telemedicine program for adults with asthma and results from proof-of-concept testing.

**Methods:** To ensure integration with practice, we used a contextually-grounded intervention development approach and May's implementation theory to design the intervention, with emphasis on systems capabilities and stakeholder needs. The intervention incorporated symptom monitoring by smart phone, smartphone telemedicine visits and self-management training with a nurse, and clinical decision support software, which provided automated calculations of asthma severity, control, and step-wise therapy. Seven adults (aged 18-40) engaged in a 3-month beta-test. Asthma outcomes (control, quality of life, FEV1) and healthcare utilization patterns were measured at baseline and end-of-study.

**Results:** Each participant received an average of 4 telemedicine visits with 94% patient satisfaction. All participants had uncontrolled asthma at baseline; by end-of-study 5/7 classified as well controlled. Mean asthma control improved 1.55 points (CI=0.59-2.51); quality of life improved 1.91 points CI=0.50-3.31), and FEV1 percent predicted increased 14.86% (CI=-3.09-32.80) with effect sizes of  $d=1.16$ , 1.09, and 0.96, respectively. Preventive healthcare utilization increased significantly (1.86 visits/year vs. 0.28/year prior, CI 0.67-2.47) as did prescriptions for controller medications (9.29 refills/year vs. 1.57 refills/year, CI 4.85-10.58).

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

**Conclusion:** Smartphone telemedicine may be an effective means to improve outcomes and deliver asthma care remotely. However, careful attention to systems capabilities and stakeholder acceptability is needed to ensure successful integration with practice.

**Clinical Trials registration #:** NCT03648203

**Funding:** Research reported in this publication was supported by Sigma Theta Tau, Epsilon Xi. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.

# TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

## Introduction

Asthma remains one of the most common chronic health conditions, affecting 8.2% of adults, of which approximately 63% have persistent symptoms.<sup>1,2</sup> Typically, correct use of controller medication and effective self-management can alleviate symptoms, prevent exacerbations, and reduce risk of long-term lung damage.<sup>3</sup> Yet while morbidity and mortality due to asthma are preventable, nearly 62% of adults with asthma remain uncontrolled, and implementation of potentially effective new interventions within real-world contexts has been limited.<sup>4</sup>

There is no doubt that careful assessment, close follow-up, medication reminders, and self-management training all improve adherence and outcomes.<sup>4</sup> However, these approaches require personnel and time resources that may not exist within over-burdened healthcare systems. With the growing shortage of primary care providers (PCP) and the increasing complexity of clinical care, it is unlikely that PCPs can carve out additional time to focus on asthma management.<sup>5</sup> For this reason, interventions that can function effectively within existing systems' constraints and improve patient outcomes *without* increasing provider burden are urgently needed.

There is growing evidence that use of e-health technology (e.g. smartphones, electronic medical record, and computer decision-support software "CDSS") can address common asthma management issues.<sup>6,7</sup> However, most technology-based interventions do not integrate with the electronic medical record (EMR), and are thus not currently clinically sustainable. While researchers may be optimistic about the ability to integrate *ex post facto*, few tech-based interventions cross the research to practice divide, typically due to unforeseen systems implementation issues or incompatibility with existing clinical workflow.

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Thus, in designing a new technology-based intervention for asthma management, we adopted a contextually grounded intervention development approach that allowed for consideration of implementation issues during the development process<sup>8</sup>. Specifically, we sought to develop a smartphone-based telemedicine program that could address common asthma management problems (e.g. patient non-adherence,<sup>9-11</sup> inaccurate symptom reporting,<sup>12, 13</sup> poor self-management,<sup>14, 15</sup> access to care,<sup>16-18</sup> and provider nonadherence to asthma guidelines<sup>19-21</sup>) and integrate with the EMR and existing clinical practice. The goal in developing the intervention was to increase the accuracy, effectiveness, and convenience of care for patients, while avoiding increased clinician burden and promoting adherence to guidelines.<sup>22-26</sup> In this manuscript, we describe the process of contextually grounded intervention development, the resulting technology, and proof of concept testing in a small, real-world sample of adult patients in a large urban medical center. We hypothesized that the intervention would show preliminary evidence of feasibility and acceptability and potential to improve asthma outcomes in younger adults with asthma.

## Methods

### Intervention Development

As shown in **Table 1**, we navigated an extensive two-year planning and development process aligning with May's implementation theory,<sup>27</sup> including identifying problems and solutions, target environments, system capabilities, key stakeholders, practice policies, and credentialing processes. Development required establishing key relationships; assembling a representative team, creating and testing the technology, obtaining approval to launch, and proof-of-concept testing with patients in the clinical setting.

*Technology Enabled Asthma Management System (TEAMS)* is a fully integrated EMR-based intervention designed for use in primary care. Based on the process described above, three technological components were selected to augment routine asthma care: (a) remote smartphone symptom monitoring, (b) synchronous smartphone telemedicine follow-up and self-management training with a nurse, and (c) computer-guided EMR assessments using built-in clinical decision-support software (CDSS). Patients recorded home-entered symptoms using their smartphones and a patient portal app (Mychart; Epic Systems Corporation, Wisconsin USA), which uploaded symptom data directly to the Epic EMR. One nurse (JRM) conducted telemedicine visits using Zoom's HIPAA-compliant secure video-conferencing platform (Zoom Inc. California USA). The nurse reviewed home-entered symptoms and entered a detailed asthma assessment into the TEAMS CDSS flowsheet (see **Figure 1**), which is a complex clinical documentation and decision-making tool embedded in the EMR. Guideline-based algorithms in the CDSS tool instantaneously calculated asthma severity, control, and provided a comparison of recommended versus prescribed step-wise therapy. The CDSS tool was designed to improve assessment accuracy, guide step-wise medication management,<sup>4</sup> inform providers, and help patients achieve

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

better asthma control. Results of the analyses were shared with the participant and evidence-based self-management training was provided using the free online resource *Let's Talk About Asthma!* e-series for smartphone developed in our prior work.<sup>28, 29</sup> A detailed progress note autogenerated by the CDSS tool (see **Figure E1**, online supplement) was filed in the EMR for each telemedicine visit. Per protocol, an EMR InBasket message with a visit summary was sent to the PCP team if the patient had uncontrolled asthma and needed medication adjustments or office follow-up, with a back-up phone call for urgent issues. To ensure safety and monitor for correct functioning of EMR algorithms, all telemedicine visits in this phase were conducted by an advanced practice nurse with IT training (JRM), and each calculated output was verified for accuracy.

CDSS calculations used National Asthma Education Prevention Program guidelines<sup>4</sup> but are adaptable to other guidelines. Program components are likely compatible with other EMRs.

### **Approach (Proof-of-concept testing)**

This study was approved by the University of Rochester Internal Review Board (RSRB67900). A mixed methods approach was used. The quantitative portion consisted of a single-arm pilot study with pre-post and longitudinal collection of outcomes over 3 months (asthma control, quality-of-life, Forced Expiratory Volume (FEV<sub>1</sub>), ED visits, hospitalizations, feasibility/acceptability surveys). The qualitative portion used descriptive methodology and open-ended interviews to capture patients' experiences and perceptions of TEAMS, to explore acceptability and perceived impact. Staggered enrollment was used to account for seasonal variation in symptoms.

### **Setting and sample**

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Participants were randomly selected from clinic rosters in an urban safety-net resident-run primary care clinic in Western NY. Eligibility criteria were: ages 18-40, with any diagnosis of current asthma, English speaking, and having a smartphone. Age range was restricted to younger adults (18-40 years) on the basis of smartphone prevalence and technology uptake. Patients with confounding comorbidities (e.g. heart failure COPD, Cystic fibrosis) and pregnant patients were excluded. Patients with psychiatric diagnoses were not excluded. Ten patients, randomly selected from clinic rosters, were screened; all had smartphones. One was ineligible on the basis of heart failure and two who were eligible could not be re-contacted after screening. The remaining seven consented and completed the beta-test (3-month duration).

### **Intervention delivery**

Written informed consent and all study procedures were performed by a trained non-medical research assistant in patients' homes due to high office-visit no-show rates. Technology set up and training occurred at the baseline visit. Participants were asked to record symptoms, medication use, and Peak Expiratory Flow (PEF) using a Microlife<sup>30</sup> digital peak flow meter (Microlife, USA) via smartphone, daily, for 3 months. A nurse (JRM) initiated follow up smartphone telemedicine visits with patients every 2-weeks until asthma control was achieved, as calculated by the TEAMS CDSS tool. All visits were scheduled by text messaging and text message reminders were sent the day prior to or the day of appointment. Following each visit, if the CDSS tool indicated that the patient's asthma was uncontrolled, a brief synopsis was sent to PCP via EMR InBasket messaging with urgent messages also conveyed via phone call. The PCP then initiated medication adjustments via e-prescribing, if warranted, and determined medically appropriate follow-up. The TEAMS nurse then helped to coordinate care and ensure follow up. Once the patient achieved good asthma control, follow up frequency decreased to

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

once a month. There was no minimum requirement for participation in self-monitoring or telemedicine visits and patients participated in each activity as often as they were motivated to. Intervention dose for each participant was tracked and correlated with outcomes.

### **Outcome Measures**

*Feasibility* was measured by: (a) frequency of participation in symptom monitoring, (b) number of visits needed to achieve/maintain asthma control, (c) duration of visits, and (d) no show and reschedule rates. Similar to clinical practice, length of visit was driven by the time it took to complete the asthma assessment, teach participants specific self-management skills, and relay follow up documentation to PCP/clinic. Thresholds for minimum or maximum intervention dose were not predefined, as the goal was not to deliver a standard intervention dose, but to assess dose needed to achieve good control or dose tolerated (e.g. frequency of voluntary participation), and relationship between intervention dose, asthma control, and quality of life.

*Efficacy.* Primary outcomes (asthma control, quality of life, and FEV<sub>1</sub> percent predicted) were collected at baseline and end of study. Asthma control and quality of life were measured using the Asthma Control Questionnaire (ACQ)<sup>31</sup> and Asthma Quality of Life Questionnaire (AQLQ), respectively.<sup>32</sup>

**ACQ.** The ACQ is a well-established 7-item questionnaire with a score range of 0-6 (lower scores represent better control). A score of  $\leq 0.75$  has a positive predictive value of 0.85 for controlled asthma, and a score of  $\geq 1.5$  has a positive predictive value of 0.88 for uncontrolled asthma.<sup>31</sup> Minimum important difference is a change score of 0.5.<sup>33</sup>

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

**AQLQ.** The AQLQ measures physical and emotional impact of disease with high test-retest reliability ( $>0.90$ ).<sup>32</sup> Averaged total scale and subscale scores range from 1-7, with higher scores representing better quality of life. Minimum important difference is 0.5 per domain and overall quality of life.<sup>34</sup>

**FEV<sub>1</sub>** was measured using Microlife digital PFMs.<sup>30</sup> FEV<sub>1</sub> percent predicted was calculated using NHANES III criteria.<sup>35, 36</sup> Number of prescriptions written by providers for asthma medications were obtained through EMR review for the year pre and post intervention. Actual refills by patients could not be accurately determined due to external pharmacies data storage procedures.

*Acceptability* was assessed at the end of the study through 1:1 interview and the *Usability Satisfaction and Ease of Use Questionnaire (USE-Q)*. The USE-Q<sup>37</sup> is a validated 21-item instrument with a 7-point Likert scale format (1=strongly disagree to 7=strongly agree). Higher scores represent more positive perceptions, with 7 being the most positive possible score and 1 representing the most negative possible score. Minimum acceptability thresholds were a score  $\geq 5$ =somewhat agree on at least 70% of USE-Q items. Exit interviews were conducted to qualitatively explore acceptability.

Demographics were collected via survey and the EMR.

### **Data analysis**

Descriptive statistics were computed for demographics, feasibility, and USE-Q data. Paired t-tests were used to compare baseline and end of study scores for ACQ, AQLQ, and FEV<sub>1</sub> percent predicted, and effect sizes (Cohen's d) were calculated. Unadjusted bivariate correlation was used to explore associations between asthma control and quality of life (ACQ, AQLQ) and

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

intervention dose (frequency of self-monitoring and telemedicine visits). Audio-recorded interviews were transcribed and qualitative content analysis techniques<sup>38</sup> were used to explore participants' perceptions of the program.

### Results

Baseline asthma and demographic data are presented in **Table 2**.

*Feasibility.* Of 42 scheduled telemedicine visits, 7 were no-shows (16%; involving 4/7 patients), 7 rescheduled (16%; involving 4/7 patients), and 28 were conducted as expected (68%). Participants averaged 4 telemedicine visits (range 3-5), for a grand mean of 114 minutes spent with the asthma telemedicine nurse (range 88-160 minutes; SD 25.07; average 61 minutes self-management training and 53 minutes nursing-assessment per participant). Participants logged symptoms remotely an average of 32 days over 3 months (range 15 to 64; SD 15.56). Participants were asked to set a daily reminder on their smartphone; no external reminders were provided for self-monitoring. Average telemedicine visit duration was 29 minutes (range 20-45 minutes), and the majority of visits (17/28; 61%) were delivered after 5pm or on weekends to accommodate participants' work schedules.

*Efficacy.* At baseline, all participants had uncontrolled asthma. At 3-months, 6/7 participants had marked reduction in symptoms with 5/7 classifying as well-controlled<sup>39</sup>. Effect sizes were large for improvements in control, quality of life, and FEV<sub>1</sub> percent predicted (d=0.96 to 1.16). **Table 3** shows pre-post scores for asthma outcomes with effect sizes and confidence intervals. On average, asthma control improved 1.55 points—more than 3 times the clinical MID. Significant improvements were seen in morning symptoms, night time wakening, activity limitations and shortness of breath, with greatest effects on reductions in wheezing (d=1.48). Quality of life improved an average of 1.91 points, nearly 4 times the minimum important

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

difference (MID). Improvements were evenly distributed across all domains (symptoms, activity limitations, emotional functioning, and environmental stimuli. There was also an average increase of approximately 15% in FEV<sub>1</sub> percent predicted.

**Table 4** shows individual peak flow graphs (extracted from the EMR) with a noticeable upward trend in PEF for most participants. Graphs for the first two participants showed downward or neutral trends. Association between number of days participants performed home self-monitoring, length of visit, and improvement in asthma control was moderate ( $r=0.67$  and  $p=0.10$ ).

An average of 2 (range 1-4; SD 1.29) InBasket messages per participant were sent by the TEAMS nurse to the participants' PCP (n=4) over 3 months, to coordinate follow-up care and medication adjustments, with 100% PCP response. As seen in **Table 3**, there were significant and clinically meaningful increases in use of preventive health services and written prescriptions for controller medications, and a corresponding decrease in prescriptions for oral corticosteroids in the year following intervention.

*Acceptability.* As shown in **Table 5**, acceptability and satisfaction was high (93.9%). At exit interviews, six of seven participants reported that the intervention “changed my life” and enabled them to take control of their asthma for the first time. Qualitative data on the perceived impact of the intervention are presented in **Table 4**.

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

### Discussion

Data from this proof-of-concept study suggest that use of an integrated smartphone and EMR/practice-based intervention might be an effective means to supplement primary asthma care and improve outcomes. The underlying importance of this approach lies in the ability to reduce barriers to accessing primary care.<sup>18</sup> Telemedicine is inherently more flexible than office care, and does not require that patients travel to a given location. Extending telemedicine into patients' homes via ubiquitously available smartphones could make communities the front-line for primary care. Because of ability to supersede geographic boundaries, smartphone technology could increase clinical reach, and may thus be the key to delivering care to underserved populations locally and globally.

Prior studies have demonstrated that use of remote monitoring, self-management training, telemedicine, smartphones, and CDSS tools, individually, can improve outcomes.<sup>40-42</sup> To our knowledge, however, this is the first intervention to combine these components into a single technological package that effectively integrates with real-world medical practice and the live EMR.

In contrast to studies that have sought to isolate and quantify the impact of individual factors,<sup>43, 44</sup> this study adopted a broad-spectrum approach with simultaneous intervention across multiple patient, provider and systems levels, as we theorized that the impact of a multifaceted program would likely be different from the impact of individual components in isolation<sup>45, 46</sup>. The marked improvement in outcomes, as evidenced by large effect sizes on key outcomes ( $d=0.96$  to  $2.62$ ), supports this holistic approach. On average, participants achieved a 15% increase in FEV1, crossing the critical clinical threshold of  $>80\%$ .<sup>39</sup> Additionally, improvements in asthma control and quality of life that were 3-4 times the minimum important difference.<sup>31, 34</sup>

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Patients' perceptions of acceptability and feasibility were high, and while participants only recorded symptoms only 33% of the time on average, greater engagement was associated with improved asthma control. Lastly, the significant increase in written prescriptions for controller medications and in-office PCP follow up suggest that the intervention can promote provider adherence to guideline-based care, in addition to improving patient specific outcomes.<sup>20, 47</sup>

From a systems standpoint, clinical feasibility and affordability has yet to be determined. In this small sample, no-show and reschedule rates for telemedicine visits was only slightly better than office visit attendance rates (66%), with 68% of telemedicine visits conducted as expected<sup>48</sup>. Further research is needed to determine cost-effectiveness and institutional capability to run a program that operates heavily during evening and weekend hours. Furthermore, given that participants required an average of 114 minutes of individualized asthma education with a nurse to achieve and maintain control, the TEAMS approach is likely to require greater upfront investment by insurers and the medical community to achieve long-term societal gain. Yet, it is abundantly clear that current approaches to "feasible and affordable care" are not effective, as the majority of patients with asthma remain chronically uncontrolled. Thus, it may be necessary to stretch healthcare boundaries and explore ways to make *effective care affordable*, rather than perpetuating systems that are *affordable* but largely *ineffective*. In short, moving towards an aggressively proactive rather than reactive approaches to asthma management is essential to changing long-term health trajectories.<sup>46</sup>

*Limitations.* This proof-of-concept study used a small sample. Patients were predominantly younger, minority, lower SES, lower health-literacy, with moderate/severe uncontrolled asthma, and the intervention was delivered by a single nurse. Further research in a larger and more representative population, with diverse interventionists is needed to replicate

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

findings, evaluate who the intervention is most effective for, and determine if all intervention components are necessary to achieve similar outcomes.

Despite limitations, we believe these data are compelling, and the processes delineated herein will be useful to those seeking to develop and implement technology-based clinical interventions. Several important lessons were learned: First, the technology took nearly two years to conceptualize, build, and integrate into practice, which was longer than anticipated. The majority of this time was spent navigating systems level barriers, gaining access to EMR build/programming environments, and getting healthcare provider buy-in. It is well-known that many potentially effective interventions are never integrated into clinical practice or the EMR. Our experience suggests that this may be partly due to failure to account for powerful real-world constraints. As seen throughout the development process (Table 1), we found that wherever the intervention disrupted existing practice (even by small amounts), it was met with resistance. Conversely, by avoiding workflow changes and carefully incorporating stakeholder feedback, we were able to minimize resistance and increase support for the intervention. It is also worth noting that even with using a contextually-grounded intervention development approach, where the intervention was crafted to the clinical context, there was still need for additional on-the-ground customization to account for unanticipated barriers (e.g. trouble engaging patients in office settings; preference of clinic providers to delegate use of the CDSS tool to nursing care). Thus, the final intervention that was implemented was noticeably different than originally conceptualized. Use of focus groups, interviews, community engagement studios, and close collaboration with key stakeholders are important precursors to developing a clinically sustainable intervention.<sup>27</sup> Additionally, careful negotiation of institutional practices for new EMR build and IT and administrative support will be essential, as there are substantial barriers to

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

new technology within the EMR due to potential for far-reaching negative systems impact.

Based on these experiences, we conclude that use of advanced EMR, CDSS, and smartphone technology has strong potential to improve asthma care, but premature intervention development without sufficient groundwork could be detrimental to long-term success.

## References

1. CDC. National Health Interview Survey (NHIS) data: 2011 lifetime and current asthma, <http://www.cdc.gov/asthma/nhis/2011/data.htm>. (2012).
2. CDC. Asthma Severity among Adults with Current Asthma, [http://www.cdc.gov/asthma/asthma\\_stats/severity\\_adult.htm](http://www.cdc.gov/asthma/asthma_stats/severity_adult.htm) (2016).
3. CDC. Uncontrolled asthma among persons with current asthma, [http://www.cdc.gov/asthma/asthma\\_stats/uncontrolled\\_asthma.htm](http://www.cdc.gov/asthma/asthma_stats/uncontrolled_asthma.htm) (2014).
4. National Asthma Education and Prevention Program. *Expert Panel Report 3: Guidelines for the diagnosis and management of asthma*. Bethesda, Md.: National Heart Lung and Blood Institutes, National Institutes of Health, Publication No. 08-5846, 2007.
5. Petterson SM, Liaw WR, Phillips RL, Jr., et al. Projecting US primary care physician workforce needs: 2010-2025. *Ann Fam Med* 2012; 10: 503-509. 2012/11/15. DOI: 10.1370/afm.1431.
6. Challenges and Barriers to Clinical Decision Support (CDS) Design and Implementation Experienced in the Agency for Healthcare Research and Quality CDS Demonstrations. In: Quality AfHRA, (ed.). Rockville, MD: U.S. Department of Health and Human Services, 2010.
7. de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, et al. Mobile phone messaging for facilitating self-management of long-term illnesses. *Cochrane Database Sys Rev* 2012; 12: CD007459. Meta-Analysis  
Research Support, Non-U.S. Gov't  
Review 2012/12/14. DOI: 10.1002/14651858.CD007459.pub2.
8. Baptista Nunes M, Tiago Martins J, Zhou L, et al. Contextual sensitivity in grounded theory: The role of pilot studies. *Journal of Business Research Methods* 2010; 8: 73-84.
9. Lee JX, Wojtczak HA, Wachter AM, et al. Understanding asthma medical nonadherence in an adult and pediatric population. *J Allergy Clin Immunol Pract* 2015; 3: 436-437. 2015/01/23. DOI: 10.1016/j.jaip.2014.11.022.
10. Thier SL, Yu-Isenberg KS, Leas BF, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. *Manag Care* 2008; 17: 48-52, 55-47.
11. Deshpande M, Chewning B, Mott D, et al. Asthma medication use among U.S. adults 18 and older. *Res Soc Admin Pharm* 2014; 10: e113-123. DOI: 10.1016/j.sapharm.2014.02.006.
12. Janssens T, Verleden G, De Peuter S, et al. Inaccurate perception of asthma symptoms: a cognitive-affective framework and implications for asthma treatment. *Clin Psychol Rev* 2009; 29: 317-327. DOI: 10.1016/j.cpr.2009.02.006.
13. Kaptein AA, Klok T, Moss-Morris R, et al. Illness perceptions: impact on self-management and control in asthma. *Curr Opin Allergy Clin Immunol* 2010; 10: 194-199. DOI: 10.1097/ACI.0b013e32833950c1.
14. Peytremann-Bridevaux I, Arditi C, Gex G, et al. Chronic disease management programmes for adults with asthma. *Cochrane Database Sys Rev* 2015: CD007988. DOI: 10.1002/14651858.CD007988.pub2.
15. Powell H and Gibson PG. Options for self-management education for adults with asthma. *Cochrane Database Sys Rev* 2003: CD004107. DOI: 10.1002/14651858.CD004107.

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

16. Bousquet J, Bousquet PJ, Godard P, et al. The public health implications of asthma. *Bull World Health Organization* 2005; 83: 548-554. 2005/09/24. DOI: S0042-96862005000700016 [pii].
17. Valerio M, Cabana MD, White DF, et al. Understanding of asthma management - Medicaid parents' perspectives. *Chest* 2006; 129: 594-601. DOI: 10.1378/chest.129.3.594.
18. Syed ST, Gerber BS and Sharp LK. Traveling towards disease: transportation barriers to health care access. *Journal of community health* 2013; 38: 976-993. Review 2013/04/02. DOI: 10.1007/s10900-013-9681-1.
19. Yawn BP, Rank MA, Cabana MD, et al. Adherence to Asthma Guidelines in Children, Tweens, and Adults in Primary Care Settings: A Practice-Based Network Assessment. *Mayo Clin Proc* 2016; 91: 411-421. 2016/03/06. DOI: 10.1016/j.mayocp.2016.01.010.
20. Okelo SO, Butz AM, Sharma R, et al. Interventions to modify health care provider adherence to asthma guidelines: a systematic review. *Pediatrics* 2013; 132: 517-534. 2013/08/28. DOI: 10.1542/peds.2013-0779.
21. Wisnivesky JP, Lorenzo J, Lyn-Cook R, et al. Barriers to adherence to asthma management guidelines among inner-city primary care providers. *Ann All Asthma Immunol* 2008; 101: 264-270. DOI: 10.1016/S1081-1206(10)60491-7.
22. Holley S, Morris R, Knibb R, et al. Barriers and facilitators to asthma self-management in adolescents: A systematic review of qualitative and quantitative studies. *Pediatr Pulmonol* 2017; 52: 430-442. DOI: 10.1002/ppul.23556.
23. Holley S, Walker D, Knibb R, et al. Barriers and facilitators to self-management of asthma in adolescents: An interview study to inform development of a novel intervention. *Clinical & Experimental Allergy* 2018; [ahead of press] Mar 23. DOI: 10.1111/cea.13141.
24. Miles C, Arden-Close E, Thomas M, et al. Barriers and facilitators of effective self-management in asthma: systematic review and thematic synthesis of patient and healthcare professional views. *NPJ primary care respiratory medicine* 2017; 27: 57. 2017/10/11. DOI: 10.1038/s41533-017-0056-4.
25. Normansell R and Welsh E. "Asthma can take over your life but having the right support makes that easier to deal with." Informing research priorities by exploring the barriers and facilitators to asthma control: a qualitative analysis of survey data. *Asthma Res Pract* 2015; 1: 11. 2015/09/29. DOI: 10.1186/s40733-015-0011-5.
26. Pelaez S, Lamontagne AJ, Collin J, et al. Patients' perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. *BMC Pulm Med* 2015; 15: 42. 2015/04/25. DOI: 10.1186/s12890-015-0044-9.
27. May C. Towards a general theory of implementation. *Implement Science* 2013; 8: 1-14.
28. Mammen J, Rhee H and Arcoleo K. Smartphone Guide to Asthma Self-Management. Rochester, NY: University of Rochester School of Nursing, 2017.
29. Mammen JR, Rhee H, Atis S, et al. Changes in asthma self-management knowledge in inner city adolescents following developmentally sensitive self-management training. *Patient Education & Counseling* 2018; 101: 687-695. DOI: 10.1016/j.pec.2017.10.016.
30. Microlife. *Microlife PF100 Peak Flow Meter*. n.d.: Microlife USA, Inc.
31. Juniper EF, Bousquet J, Abetz L, et al. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. *Respiratory Medicine* 2006; 100: 616-621. 2005/10/18. DOI: 10.1016/j.rmed.2005.08.012.

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

32. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. *Chest* 1999; 115: 1265-1270. Research Support, Non-U.S. Gov't 1999/05/20.
33. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respiratory Medicine* 2005; 99: 553-558. Clinical Trial Randomized Controlled Trial 2005/04/13. DOI: 10.1016/j.rmed.2004.10.008.
34. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. *J Clin Epidemiol* 1994; 47: 81-87. Research Support, Non-U.S. Gov't 1994/01/01.
35. CDC. Spirometry reference values, <https://www.cdc.gov/niosh/topics/spirometry/refcalculator.html> (2018).
36. Hankinson JL, Odencrantz JR and Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999; 159: 179-187. 1999/01/05. DOI: 10.1164/ajrccm.159.1.9712108.
37. Lund A. Measuring usability with the USE Questionnaire. *STC Usability SIG Newsletter* 2001; 8.
38. Hsieh HF and Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res* 2005; 15: 1277-1288. DOI: 10.1177/1049732305276687.
39. National Heart Lung and Blood Institutes [NHLBI]. Asthma care quick reference. Bethesda, Md.: National Asthma Education and Prevention Program, 2011.
40. Chongmelaxme B, Lee S, Dhippayom T, et al. The Effects of Telemedicine on Asthma Control and Patients' Quality of Life in Adults: A Systematic Review and Meta-analysis. *J Allergy Clin Immunol Pract* 2019; 7: 199-216 e111. 2018/07/29. DOI: 10.1016/j.jaip.2018.07.015.
41. Dokbua S, Dilokthornsakul P, Chaikyapapruk N, et al. Effects of an Asthma Self-Management Support Service Provided by Community Pharmacists: A Systematic Review and Meta-Analysis. *J Manag Care Spec Pharm* 2018; 24: 1184-1196. 2018/10/27. DOI: 10.18553/jmcp.2018.24.11.1184.
42. Yawn BP, Wollan PC, Rank MA, et al. Use of Asthma APGAR Tools in Primary Care Practices: A Cluster-Randomized Controlled Trial. *Ann Fam Med* 2018; 16: 100-110. 2018/03/14. DOI: 10.1370/afm.2179.
43. Poureslami IP, Shum JM, Lester RM, et al. A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2018: 1-13. 2018/07/14. DOI: 10.1080/02770903.2018.1500583.
44. Boulet LP, Boulay ME, Gauthier G, et al. Benefits of an asthma education program provided at primary care sites on asthma outcomes. *Respir Med* 2015; 109: 991-1000. 2015/07/15. DOI: 10.1016/j.rmed.2015.05.004.
45. Wagner E, Austin B and Von Korff M. Organizing care for patients with chronic illness. *Milbank Q* 1996; 74: 511-544.
46. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. *Health Aff (Millwood)* 2001; 20: 64-78. 2002/01/31. DOI: 10.1377/hlthaff.20.6.64.

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

47. Hull SA, McKibben S, Homer K, et al. Asthma prescribing, ethnicity and risk of hospital admission: an analysis of 35,864 linked primary and secondary care records in East London. *NPJ Primary Care Respiratory Medicine* 2016; 26: 16049. 2016/08/19. DOI: 10.1038/npjpcrm.2016.49.
48. Fischer H, Moore S, Johnson T, et al. Appointment reminders by text message in a safety net health care system: a pragmatic investigation. *eGEMs (Generating Evidence & Methods to improve patient outcomes)* 2017; 1. DOI: doi.org/10.13063/egems.1293.
49. Department of Health and Human Services. Poverty guidelines, <https://aspe.hhs.gov/poverty-guidelines>.

# TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

TABLE 1. Process of contextually grounded intervention development

	Key components of process	Examples
<b>PLANNING STAGE</b>		
Problems and potential solutions	<ul style="list-style-type: none"> <li>Identify target population and specific problems</li> <li>Assess population capabilities, barriers, facilitators</li> <li>Define approaches that might work for problem and population using prior evidence and theory</li> </ul>	<p><b>Population:</b> Adults at risk for uncontrolled asthma (urban, minority, underserved, low SES, low health literacy)</p> <p><b>Problems:</b> Poor access to care; No show and transportation issues, Nonadherence; Poor follow-up; Poor self-management.</p> <p><b>Opportunity:</b> 85% adults &lt; 40 years use smartphones regularly</p>
Target environment	<ul style="list-style-type: none"> <li>Identify environments with access to target population</li> <li>Assess clinical capability, preparedness, and willingness to adopt a new intervention</li> <li>Identify current clinical structure (physical resources, ways of operating, workflow and scheduling patterns)</li> <li>Develop awareness of general and specific barriers (staff, provider, or clinic resource limitations)</li> <li>Determine approaches that might work for clinical context, patient population, and identified problems</li> </ul>	<p><b>Environment:</b> Urban primary care “safety-net” practice</p> <ul style="list-style-type: none"> <li>Practice willing to support a tech-based asthma intervention <u>if no negative impact on workflow</u></li> <li>EMR/smartphone intervention run by nurses would be acceptable and integrate with practice</li> <li>Modification to work flow/documentation patterns would not be supported by providers due to increased work burden</li> <li>Limited availability of clinic appointments = delayed follow up.</li> <li>Hours of operation: Weekdays until 4:30pm, conflicts with patient needs for afterhours and weekend care</li> </ul>
System capabilities	<ul style="list-style-type: none"> <li>Identify system capabilities (technological, programmatic, IT resources, supports/barriers)</li> <li>Identify implementation barriers (e.g. moratorium on new EMR build, anticipated build time and available build resources (personnel and systems access issues), willingness to support novel research-based build)</li> </ul>	<p><b>Capabilities:</b> Symptoms can be monitored remotely with smartphones via patient portal to EMR interface</p> <ul style="list-style-type: none"> <li>Guideline-based algorithms and decision support tools in EMR can minimize inaccuracies in clinical care</li> <li>Home-based telemedicine can improve access to care</li> </ul> <p><b>Barriers:</b> institutional cap on EMR build &gt; 10 hours - requires formal review for priority and funding; research considered lower priority than clinical applications; limited funding available; initial plan to have clinic nurses do telemedicine visit was found to be non-viable due to patient need for evening and weekend visits, resulting in use of dedicated nurse interventionist</p>
Key stakeholders	<ul style="list-style-type: none"> <li>Define potential impact of intervention (development and implementation) on patient, staff, and systems revenue or resources to identify stakeholders</li> <li>Recognize and respect needs and perspectives of stakeholders who may impact intervention uptake (e.g. patient, community, support staff, nursing, provider, administrative, IT and data security, research, reporting, insurers)</li> </ul>	<p>Interviews and community engagement studios to engage:</p> <ul style="list-style-type: none"> <li>Admin: (support for hybrid clinical/research program)</li> <li>Medical faculty (support for program w/ Resident participation)</li> <li>Residents: (support shared patient management; in-basket notification of nursing assessments; <u>not supportive</u> of any workflow change/disruption; low interest in using CDSS)</li> <li>Nursing: (gatekeeper for clinical communication pathways; open to workflow changes if practicable, interested in maximizing scope of practice, including use of CDSS and telemedicine follow up)</li> <li>IT department (gatekeepers for new build; review/approve build)</li> </ul>

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

		<ul style="list-style-type: none"> <li>• Research community (requires rigorous science/data)</li> <li>• Patient and community (feedback on design, problems)</li> </ul>
Practice policies	<ul style="list-style-type: none"> <li>• Identify practice policies and incorporate into design</li> </ul>	<ul style="list-style-type: none"> <li>• Factor for established communication pathways, scheduling procedures, usual follow up protocols</li> <li>• Identify internal "champions" who can facilitate implementation</li> </ul>
Credentialing and approval	<ul style="list-style-type: none"> <li>• Determine what certifications may be necessary to obtain approval or facilitate development of the intervention (e.g. specific build or reporting certifications)</li> <li>• Identify needed permissions (e.g. IRB, clinical administration, provider/staff approvals or "buy-in")</li> </ul>	<ul style="list-style-type: none"> <li>• (Urgent) Epic builder certification of researcher needed due to limited build resources; EMR build had to be performed by researcher, and administrative approval was needed at multiple levels to support this</li> <li>• (Delayed) Asthma educator certification necessary for eventual insurance billing</li> </ul>
Funding sources	<ul style="list-style-type: none"> <li>• Identify immediate funding sources and potential for long-term sustainable funding</li> </ul>	<ul style="list-style-type: none"> <li>• Immediate: departmental and research funding</li> <li>• Eventual: foundation funding → insurer reimbursement</li> <li>• Current insurer policy does not reimburse for site to home telemedicine by nursing for asthma care; however demonstration of long-term cost savings could be used to drive policy changes</li> </ul>

### DEVELOPMENT STAGE

Establishing relationships, Assembling the team	<ul style="list-style-type: none"> <li>• Representative of key internal stakeholders</li> </ul>	<ul style="list-style-type: none"> <li>• Relationships: Faculty/staff, patient and community, administrative, clinical, research, and information technology</li> <li>• Team members: clinical, research, IT, administration, pharmacy, community liaison</li> </ul>
Developing technology – a systems approach	<ul style="list-style-type: none"> <li>• Translate guidelines to algorithms conceptually</li> <li>• Draft (code), revise and test technology</li> <li>• Build for compatibility with existing workflow</li> <li>• Minimize disturbances to current clinical patterns</li> <li>• Seek additional feedback from key stakeholders</li> <li>• Modify algorithms and output based on feedback</li> </ul>	<ul style="list-style-type: none"> <li>• Determine quantity, granularity, and specificity of data capture (categorical, interval, or narrative)</li> <li>• Determine approach to data entry (e.g. smartform, flowsheet)</li> <li>• Assess if data capture approach is well situated for reporting and statistical analyses and impact on workflow of data entry method</li> <li>• Identify evidence-based guidelines and write code for CDSS</li> <li>• Obtain expert review of CDSS (clinician, pharmacist, nursing)</li> <li>• Test program comprehensively for analytic functioning—200 unique clinical scenarios evaluated across multiple iterations</li> <li>• Design + test CDSS auto-generated progress note, obtain clinician review of note content and format</li> </ul>

### IMPLEMENTATION STAGE

Final approvals and Launch	<ul style="list-style-type: none"> <li>• Review of the final product by stakeholders</li> </ul>	<ul style="list-style-type: none"> <li>• Clinic permission to launch</li> <li>• IRB approvals</li> <li>• Beta testing with patient feedback and revision as indicated</li> </ul>
----------------------------	---	--

*Notes: CDSS=Clinical decision support software; EMR=Electronic medical record; IT=Information technology; SES=Socioeconomic status*

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

TABLE 2. Sample Baseline Characteristics (n=7)

<b>Variable</b>	<b>N (%)</b>
Single (% Yes)	6 (86)
Low income <sup>a</sup> (% Yes)	5 (71)
Employed full time (% Yes)	5 (71)
Public insurance (% Yes)	4 (57)
High School Graduate (% Yes)	5 (71)
Sex (% Female)	6 (86)
Comorbid mental illness (% Yes) <sup>b</sup>	5 (71)
Comorbid substance use disorder (% Yes) <sup>c</sup>	4 (57)
Ethnicity (%)	
African American	4 (57)
Hispanic/Latino	2 (29)
Caucasian	1 (14)
Any Controller Medication Use Past Month (% Yes)	3 (43)
Asthma Control (%)	
Well-controlled	0
Not-well-controlled	2 (29)
Very-poorly-controlled	5 (71)
Asthma Severity (%)	
Mild persistent	0
Moderate persistent	2 (29)
Severe persistent	5 (71)
	<b>Mean (SD)</b>
Age	29.5 (5.22)
Years diagnosed with asthma	16.57 (8.33)

<sup>a</sup> Low income: < 200% US Federal poverty level (\$12,140 individual; \$25,100 for a family of four)<sup>49</sup>

<sup>b</sup>Mental illness: bipolar, PTSD, panic disorder, anxiety/depression

<sup>c</sup>Substance use disorders: marijuana, tobacco, alcohol

TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

TABLE 3. Change pre to post intervention for key clinical asthma outcomes

	Baseline Mean (SD)	End Mean (SD)	Change Mean (SD)	Effect (d)	P-value	CI
<b>ACQ<sup>a</sup></b>	2.75 (1.27)	1.20 (1.35)	-1.55 (1.02)	1.16	<b>0.007</b>	0.59-2.51
Morning symptoms	2.00 (0.82)	1.00 (1.00)	1.00 (1.00)	1.09	<b>0.045</b>	0.075-1.93
Nighttime wakening	2.43 (1.71)	0.57 (1.13)	1.86 (1.95)	1.28	<b>0.038</b>	0.052-3.66
Activity limitations	3.00 (1.92)	1.73 (1.90)	1.57 (1.27)	0.66	<b>0.017</b>	0.40-2.75
Shortness of breath	4.00 (1.52)	2.00 (2.00)	2.00 (1.00)	1.13	<b>0.002</b>	1.08-2.93
Wheezing	2.86 (1.22)	1.00 (1.29)	1.87 (1.34)	1.48	<b>0.011</b>	0.61-3.10
SABA use	2.14 (2.04)	1.29 (1.60)	0.86 (1.57)	0.46	0.20	-0.60-2.31
<b>AQLQ<sup>a</sup></b>	3.69 (1.27)	5.60 (2.13)	1.91 (1.53)	1.09	<b>0.016</b>	0.50-3.31
Symptom domain	3.49 (1.60)	5.69 (2.13)	2.20 (1.52)	1.17	<b>0.009</b>	0.79-3.61
Activity domain	4.12 (1.15)	5.57 (2.21)	1.45 (1.44)	0.82	<b>0.037</b>	0.12-2.79
Emotional domain	3.49 (1.59)	5.77 (1.99)	2.29 (2.17)	1.27	<b>0.032</b>	0.28-4.29
Environmental domain	3.39 (1.18)	5.18 (2.29)	1.79 (1.86)	0.98	<b>0.044</b>	0.06-3.51
<b>FEV<sub>1</sub>%Pred</b>	76.14% (17.79)	91.00% (12.99)	14.86% (19.4)	0.96	0.089	-3.09-32.80
	Year prior (SD)	Year post (SD)	Change (SD)	Effect (d)	P-value	CI
<b>Emergency visits</b>	0.28 (0.76)	0 (.00)	0.28 (0.76)	0.52	0.356	-0.41-0.98
<b>Preventive office visits</b>	0.29 (0.49)	1.86 (0.69)	1.57 (0.96)	2.62	<b>0.005</b>	0.67-2.47
<b>Prescriptions - controller medication</b>	1.57 (2.70)	9.29 (3.50)	7.71 (3.09)	2.47	<b>0.001</b>	4.85-10.58
<b>Prescriptions - SABA</b>	4.29 (3.30)	10.57 (7.02)	6.29 (6.55)	1.14	<b>0.044</b>	0.22-12.34
<b>Prescriptions - OCS</b>	0.43 (0.79)	0.14 (0.38)	0.28 (0.95)	0.47	0.457	-0.59-1.17

Abbreviations. ACQ=Asthma Control Questionnaire; AQLQ=Asthma Quality of Life Questionnaire; OCS=oral corticosteroid; SABA=short acting beta agonist

<sup>a</sup>Minimum important difference = 0.5 per domain and total score; Large effect size (d) is considered >0.80;

TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

TABLE 4. Key outcomes and qualitative data by case for patients participating in TEAMS Beta test

P# (Sex) Race Age	Graph of daily PEF (extracted from EMR) Baseline → End	Measure	Pre	Post	Perceived impact of intervention (Exit interviews)
P#1 (F) AA 40		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries <sup>a</sup>	4 2.43 67	4 1.19 68 3 29	[Before] I didn't realize my asthma wasn't controlled, I was wheezing but I just thought I had a cold all the time.... I thought I was doing pretty good even though I be out of breath. But when I started using [the peak flow] I saw the numbers and realized I couldn't breathe, and that made me want to get my lungs healthy ... I'll be honest, I didn't used to take my pump, but now I use it every day.
P#2 (F) AA 32		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	2.14 3.97 85	1.29 5.84 84 4 15	The program helped me recognize the symptoms of my asthma...I learned if you don't take your control medicine you can scar your lungs—that got me to pay attention! Now that I'm daily taking my medicine—it's given me a whole 'nother breath...I thought I didn't need it, 'til I found out how to use it and what it does for your body. I'm recommending this to my family and friends—I'm spreading the word!
P#3 (F) HL/AA 29		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	5 1.88 46	1.71 4.59 100 5 64	I realized I have the right to control my asthma. First time we met I was crying cause all I wanted to do is breathe, but I felt powerless. This changed my life—I'm like 100% better. [Before] I didn't use my inhalers cause of how I was raised. Now I take my [control inhaler] every day. ... I had a medication that could've been helping me the whole time, but I didn't know what it was for, so I'm not gonna take it!
P#4 (F) AA 24		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	2.29 4.41 102	0.43 6.94 103 4 24	I used to have symptoms for hours every day, and now I almost never do. I take my control inhaler every day and I work out—and I couldn't do that before. And before, if I had an asthma attack, I wouldn't take my inhaler, I would've just called the ambulance and gone to the hospital. But [now] I take it and it works! I have the knowledge and confidence that I can take care of myself—This changed my life!
P#5 (M) AA 29		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	2.43 3.28 85	0.43 6.88 95 3 24	I'm not really having symptoms anymore, maybe once a week. Before I was wheezing all the time, and I didn't have any medication, and I didn't know what was causing it. I was suffering. Now, I take my control medication every day. It takes a load off a person when you get the education and you can monitor it and control it...it changed my life dramatically. I can breathe, and I can control it. I feel like a regular person. It's amazing. I recommend <i>anyone</i> do this.
P#6 (F) C 24		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	1.57 5.50 80	0.29 6.81 103 5 34	I'm more aware and more educated about my symptoms now, and I take my control meds every day. I used to wait out my symptoms, thinking "it'll go away, it's OK." I'm less accepting of symptoms now because I know I'm doing damage—I was never taught that. It's kind of embarrassing ...I'm a nurse and I should've known these things. Now I can better educate my patients and even my doctors.
P#7 (F) HL 24		ACQ AQLQ FEV <sub>1</sub> %pred # Televisits # Entries	1.71 4.47 68	0.29 6.94 84 4 36	(Crying) Six months ago I was scared. I was out of work for a month because of asthma. Now I'm not scared and I know what to do to prevent something small from getting big. Before, I never paid for my control inhaler because it was expensive and I didn't know why I should get it when I could use the cheap one. I don't freak out now if I leave home without my rescue inhaler because I almost never need it.

Notes. <sup>a</sup>Entries = home entered symptoms. AA=African American; ACQ=Asthma Control Questionnaire (Range 0-6; Lower scores represent better asthma control; < 1.5 is predictive of controlled asthma); AQLQ=Asthma Quality of Life Questionnaire (Range 1-7; Higher scores represent better quality of life); C=Caucasian; HL= Hispanic/Latino; F=Female; M=Male; P#=Participant(#); Visits=Telemedicine visits with a Nurse; Recordings=daily home symptom and peak flow recordings via smartphone patient portal. (PEF graph images extracted from the EMR show peak flow over time and have been flipped to display data in left to right chronological order. PEF images © 2019 Epic Systems Corporation. Used with permission.

# TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

TABLE 5. Item scores for the Usability, Satisfaction and Ease of Use Questionnaire

	Mean	Range (1-7)	SD
It helps me be more effective.	7	7	0
It helps me be more productive.	6.86	6-7	0.378
It is useful.	6.71	6-7	0.488
It gives me more control over the activities in my life.	6.71	6-7	0.488
It makes the things I want to accomplish easier to get done.	6.43	4-7	1.134
It saves me time when I use it.	6.14	4-7	1.215
It does everything I would expect it to do.	6.43	4-7	1.134
It is easy to use.	6.29	5-7	0.951
It is easy to use. It is simple to use.	6.86	6-7	0.378
It is user friendly.	6.86	6-7	0.378
It requires the fewest steps possible to accomplish what I want to do with it.	6.57	5-7	0.787
I learned to use it quickly.	6.57	5-7	0.787
I easily remember how to use it.	6.57	6-7	0.535
It is easy to learn to use it.	6.71	6-7	0.488
I am satisfied with it.	6.86	6-7	0.378
I would recommend it to a friend.	6.57	5-7	0.787
It is fun to use.	6.43	4-7	1.134
It works the way I want it to work.	6.43	4-7	1.134
It is wonderful.	6.43	5-7	0.976
I feel I need to have it.	6.14	3-7	1.574
It is pleasant to use.	6.43	4-7	1.134
Average score for survey	6.57	5.6-7	0.654

Notes: Likert scale range 7=Very satisfied to 1=Very dissatisfied

# TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Nurse (computer) side - TEAMS CDSS tool:

\*Values corresponding with uncontrolled asthma highlight in red with (!) 0700

SUBJECTIVE (Quick tab #) = (Narrative text)	
Patient perceived asthma control	1 = Not well controlled
Days per week with asthma symptoms	5 = Five days per week (!)
Wake up due to asthma per week	3 = Three nights per week (!)
Rescue inhaler for active symptoms per week	1 = One day per week
Rescue inhaler use BEFORE exercise	0 = Rarely using
Activity limitations due to asthma	1 = Some limitation (!)
Current respiratory illness	0 = No respiratory illness
Any smoking in the past 6 months	No
NOTES	Symptoms are worse at night than daytime...
OBJECTIVE	
Patient appearance	0 = Appears well
Respiratory effort	0 = Normal respiratory effort
Peak Flow	350
PFM personal best	450
• PFM % of personal best	78% (calculated)
FEV1 (today)	2.06
FEV1 Predicted	2.46
• FEV1 % of predicted	84% (calculated)
• FEV1 or PFM Zone	Green (calculated, FEV1 preferred)
NOTES	
NURSING ASSESSMENT	
ICS formulation details (Rx)	Fluticasone MDI 220 mcg
Remaining inhalations (# on back of ICS inhaler)	85
Maximum prescribed puffs per day (AM + PM)	2
Actual puffs ICS (AM)	1
Actual puffs ICS (PM)	0
Other asthma control medications	0 = None
Current rescue medication	Albuterol (Proair)
Actual puffs rescue inhaler (describe)	Rarely using - rationing/holding off
Any symptoms of life-threatening asthma	N = None
Asthma safety assessment	N = No Safety concerns
NOTES	Having trouble remembering nighttime dose...
ANALYSIS + RECOMMENDATIONS (Calculated)	
Asthma control	Not Well Controlled
Asthma severity (EPR3)	Moderate Persistent asthma
Guideline based assessment of controller therapy	Insufficient control medication
• Guideline recommended stepwise therapy	Step 3-4
• Provider prescribed stepwise therapy level	Step 3
• Patient using stepwise therapy level	Step 2
• Can still increase ICS by (#) puffs/day	1
• Recommended ICS adjustments	Increase to full prescribed dose
• Recommended follow up	Telemedicine follow up
NURSING PLAN	
Follow up plan	2 = Follow up in 2 weeks
Medication refill	0 = No refills needed
NOTES	Continue to work on adherence, strategies to...
PLAN: Education	
1. What is asthma; what causes symptoms	X = Demonstrates understanding
2. What happens when asthma is uncontrolled	X = Demonstrates understanding
3. How do you know if your asthma is controlled	X = Demonstrates understanding
4. Control vs. rescue medications	X = Demonstrates understanding
5. Recognizing symptoms of asthma	X = Demonstrates understanding
6. What to do during an asthma attack	
7. How to recognize life threatening asthma	
8. How to take inhalers correctly	N = Needs reinforcement !
9. How and why you should use a spacer	N = Needs reinforcement !
10. How to use a peak flow meter	
11. Asthma triggers and how to handle them	
12. Managing exercise induced asthma	
13. Keeping track of asthma symptoms	
14. Using an asthma action plan	
Personal goals for asthma management	Wants to improve exercise tolerance for basketball...
NOTES	Good return demo of inhaler technique, needs...
Total minutes asthma education	20

Patient (smartphone) side - LTAA series:

Let's Talk About Asthma® HOME

### Check your ASTHMA CONTROL:

OVER THE LAST MONTH	ALL green = WELL CONTROLLED	ANY yellow but NO red = NOT WELL CONTROLLED	ANY red = VERY POORLY CONTROLLED
symptoms	2 or LESS times a week	3 or MORE times a week	MANY times a day
night time wake up for symptoms	2 or LESS times a month	3 or MORE times a month	4 or MORE times a week
using rescue inhaler	2 or LESS times a week	3 or MORE times a week	3 or MORE times a day
activity limitations	NONE	SOME limitation	VERY limited
Peak Flow	MORE THAN 80% of best	50 to 80% of best	LESS THAN 50% of best

Your asthma is: Not Well Controlled

adapted from the National Guidelines (2007) Figure 3-4c

Let's Talk About Asthma® HOME

## Don't forget to use a Spacer!



Spacers help more medicine get in your lungs. When you use your inhaler with out a spacer a lot of the medicine gets lost.

1. Shake the inhaler and attach it to the spacer
2. Breathe OUT
3. Put the spacer mouth piece in your mouth, squirt in one puff into the chamber, and then inhale slowly through your mouth
4. Hold for 10 seconds
5. Wait 1 minute and repeat as directed
6. Clean your spacer as directed



Figure 1. Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based assessments during telemedicine visits (left), including built-in patient educational modules from the Let's Talk About Asthma series for smartphone (right) Copy right J Mammen, used with permission

# TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Figure E1. Sample progress note auto-generated by the TEAMS CDSS tool

## Progress note

### TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

#### Asthma telemedicine visit summary xx/xx/xxxx:

- Assessment: Very Poorly Controlled, likely Severe persistent asthma based on prescribed medications and symptom pattern.
- Prescribed: SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) at a MEDIUM dose (640 mcg daily) and is currently taking 2 puffs in the morning and 2 puffs at night (640 mcg daily - MEDIUM dose)
- Other asthma control medications: NONE (taking cetirizine for allergy)
- Recommended stepwise therapy is Step 5.
- The patient is currently taking Step 4 - Insufficient control medication
- Plan: Schedule office visit with PCP, Follow up virtual visit in 2 weeks

#### DETAILED NOTE BELOW

#### SUBJECTIVE

XXX was seen via Zoom (telemedicine) for nursing follow up of Asthma.

#### The patient reports the following:

Daytime symptoms Well controlled <= 2 x week	<b>Every day, throughout the day</b> (maybe 2-3x day, mostly morning or evening). Notes recurrent chest discomfort which resolves with albuterol
Night time wake up from asthma Well controlled <= 2 x month	<b>Wakes three nights a week</b>
Use of rescue inhaler for symptoms Well controlled <= 2 x week	<b>Using inhaler many times a day</b>
Activity limitations Well controlled = none	<b>Some limitation</b>

Patient perceived asthma control: **Very poorly controlled**

Current respiratory illness: Feels fine

Any smoking in the past 6 months: **Yes**

Any symptoms of life-threatening asthma: No

NOTES: noticing chest discomfort all day, a pain with deep breathing, pain resolved with taking albuterol and stays away for 3 to 4 hours then returns.

#### MEDICATION USE:

Prescribed: SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) and is currently taking 2 puffs in the morning and 2 puffs at night (MEDIUM dose)—fully adherent.

*Low dose is equal or less than 540mcg; High dose is greater than 1080mcg*

Taking any additional long acting beta agonist or leukotriene inhibitor: NONE (taking cetirizine for allergy)

Rescue medication: Albuterol inhaler - used about 4-5 times a day - takes prior to AM/PM Symbicort as recommended, and then a couple of times during the day

#### Most recent patient self-reported data (MyChart smartphone monitoring) shows:

	4/16/2019	4/15/2019	4/14/2019	4/5/2019	4/3/2019	4/1/2019
<b>Time</b>	<b>6:00 AM</b>	<b>7:01 AM</b>	<b>9:22 AM</b>	<b>7:52 AM</b>	<b>5:44 AM</b>	<b>2:23 PM</b>
<b>Did you have ANY SYMPTOMS of asthma in the past 24 hours?</b>	I had SOME asthma symptoms					
<b>What was your</b>	358	357	352	401	318	533

## TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

### PEAK FLOW today?

#### OBJECTIVE

Appears well - Normal effort with respiration

Peak flow today via digital PEF meter is 481 L/min, which is 100% of personal best (481)

FEV1 (today): 3.35 FEV1 Predicted: 4.15 • FEV1 % of predicted: 81

- FEV1 or PFM Zone: Green

#### ASSESSMENT

No current safety concerns: Symptoms have decreased over all, but noticing regular chest discomfort - needs to follow up in office ASAP and may need stepwise increase to bring symptoms under control faster. Should follow up ASAP for chest pain.

#### EPR-3 calculated asthma assessment:

Asthma control: Very poorly controlled

Asthma severity (EPR3): Severe persistent asthma

Guideline based assessment of controller therapy: Insufficient control medication

- Guideline recommended stepwise therapy: Step 5
- Provider prescribed stepwise therapy level: 4
- Patient using stepwise therapy level: 4
- Recommended ICS adjustments: Taking maximum dose prescribed by provider
- Recommended follow up: Follow up with PCP ASAP

Based on DHHS. National Heart Lung & Blood Institute. [Asthma Care Quick Reference: Diagnosing and Managing Asthma](#)

#### PLAN

<b>Asthma Education covered this visit:</b>	
What is asthma + what causes symptoms	
What happens when asthma is uncontrolled	Demonstrates understanding
How do you know if your asthma is controlled?	Demonstrates understanding
Control vs. rescue medications	Demonstrates understanding
Recognizing symptoms of asthma	Demonstrates understanding
What to do during an asthma attack	Demonstrates understanding
Life threatening asthma symptoms	Demonstrates understanding
How to take inhalers correctly	Demonstrates understanding
How and why you should use a spacer	Demonstrates understanding
How to use a peak flow meter	Demonstrates understanding
Asthma triggers and how to handle them	Demonstrates understanding
Managing exercise induced asthma	Demonstrates understanding
Keeping track of symptoms	
Using an asthma action plan	

Personal goals for asthma management: Wants to get rid of chest discomfort; Total minutes asthma education: 35  
Follow up plan: Schedule office visit with PCP ASAP, Follow up virtual visit in 2 weeks. Reinforced need to follow up in office ASAP; given # to call clinic since he did not have it.